Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 250.60B | 242.43B | 239.29B | 223.28B | 202.44B |
Gross Profit | 92.23B | 92.89B | 91.77B | 87.05B | 78.82B |
EBITDA | 9.11B | 9.72B | 12.39B | 9.25B | 7.22B |
Net Income | 971.00M | 2.59B | 5.40B | 3.84B | 412.00M |
Balance Sheet | |||||
Total Assets | 203.96B | 209.53B | 211.30B | 208.31B | 207.48B |
Cash, Cash Equivalents and Short-Term Investments | 19.86B | 24.94B | 32.89B | 39.89B | 44.32B |
Total Debt | 7.37B | 9.95B | 12.63B | 15.18B | 15.43B |
Total Liabilities | 81.83B | 84.72B | 88.73B | 89.60B | 91.13B |
Stockholders Equity | 121.72B | 124.45B | 122.36B | 118.66B | 116.31B |
Cash Flow | |||||
Free Cash Flow | 5.31B | -2.86B | 1.38B | -2.78B | 20.13B |
Operating Cash Flow | 12.06B | 4.27B | 7.02B | 2.23B | 25.37B |
Investing Cash Flow | -9.60B | -8.04B | -5.48B | -5.16B | -2.02B |
Financing Cash Flow | -7.53B | -4.14B | -7.91B | -2.12B | 8.51B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | ¥347.93B | 9.03 | 1.26% | 14.62% | 68.11% | ||
76 Outperform | ¥120.02B | 12.85 | 7.64% | 3.97% | 14.83% | 62.73% | |
74 Outperform | ¥150.48B | 16.65 | 11.66% | 2.39% | 2.00% | -51.40% | |
73 Outperform | ¥140.35B | 16.81 | 1.35% | 4.06% | -2.33% | ||
69 Neutral | ¥50.27B | 50.89 | 2.86% | 1.82% | -148.67% | ||
67 Neutral | ¥277.27B | 14.70 | 6.81% | 2.50% | 5.06% | -23.65% | |
64 Neutral | ¥237.87B | 21.80 | 2.94% | 2.42% | 55.63% |
XEBIO Holdings Co., Ltd. has announced the finalization of terms for issuing stock acquisition rights as stock options, which were resolved at a recent Board of Directors meeting. This move involves the allocation of 2,500 stock acquisition rights to directors, executive officers, and employees, potentially impacting the company’s equity structure and providing incentives for key personnel.
XEBIO HOLDINGS CO., LTD. announced the issuance of stock acquisition rights as stock options to incentivize directors, executive officers, and employees. This move is intended to enhance the company’s business performance and align management priorities with shareholder interests. The issuance involves 250,000 common shares and 2,500 stock acquisition rights, with adjustments possible in case of stock splits or other corporate actions.
XEBIO Holdings CO., LTD. has completed the renovation and conditional donation of the ‘XEBIO Arena Sendai’ to Sendai City, finalizing an extraordinary loss of ¥2,370 million. The company will continue to manage the arena through its subsidiary under a 20-year management agreement, aiming to enhance regional contributions and community engagement through sports and cultural events.
XEBIO Holdings Co., Ltd. has completed the acquisition of 25,500 treasury shares at a total cost of 31,748,174 yen through market purchases on the Tokyo Stock Exchange. This move is part of a broader strategy authorized by the Board of Directors to acquire up to 3,000,000 shares, enhancing the company’s financial flexibility and potentially increasing shareholder value.
XEBIO Holdings reported a 3.4% increase in net sales for the fiscal year ending March 31, 2025, with operating profit surging by 66.6%. Despite the rise in sales and operating profit, the profit attributable to owners of the parent decreased by 62.5%, highlighting challenges in maintaining profitability. The company anticipates continued growth in net sales and operating profit for the fiscal year ending March 31, 2026, although profit attributable to owners is expected to remain relatively flat. This financial performance reflects both the company’s resilience in increasing sales and operational efficiency, and the ongoing challenges in profit retention, impacting stakeholders’ expectations.